Ozempic: weight commonly returns after stopping

Clinical follow-up and studies report that many people regain substantial weight after stopping GLP‑1 drugs such as semaglutide, and trial data show continued treatment maintained or increased weight loss while stopping led to measurable regain.

GLP‑1 receptor agonists, including semaglutide, are now widely used in the U.S. for weight loss. The topic is discussed because many people and clinicians are asking what happens after treatment is stopped. Follow-up from clinical trials and other studies has found weight regain is common after stopping these medications. The drugs are also prescribed to manage some ongoing health conditions, so stopping can affect disease management for some people. Key facts: - Weight regain after stopping GLP‑1 treatment is commonly reported in follow-up studies. - In trials, people who continued semaglutide kept losing weight, while those who stopped regained almost 7% of body weight during the monitored period. - Other studies report that up to two‑thirds of lost weight can return within a year after stopping GLP‑1 medications. - GLP‑1 medications are also used to treat some chronic conditions; stopping may change how those conditions are managed. - Many experts report using the "lowest effective dose" for maintenance, though no studies directly compare tapering or dose‑spacing approaches. - Serious adverse events are described as rare but possible, and risk discussions are part of clinical care. Summary: Evidence indicates that maintaining weight loss after stopping GLP‑1 medications is challenging and that continued treatment was more effective at sustaining loss in trial follow‑up. The article reports that clinicians may discuss dose strategies, tapering, or alternative approaches based on individual circumstances, and that decisions are presented as personal and individualized.